"More than 95 percent of our clients are international, mainly coming from the US or focusing on the US market."
In Conversation
"In terms of international collaboration, we are receiving help from Japan and we already send some of our researchers to this country in order to study…
"In Taiwan, one of our most valuable differentiators is our strong commitment to further enhancing the country’s R&D ecosystem by operating as a knowledge and expertise…
"Our business model and development approach are very different from these of most other Taiwanese biotech companies, which usually exclusively rely on the stock market and…
"My vision for Orient EuroPharma is to keep this two-fold focus at the core of our development strategy: on one hand, further attracting new, innovative and/or…
"My vision for Orient EuroPharma is to keep this two-fold focus at the core of our development strategy: on one hand, further attracting new, innovative and/or…
"Our single-payer system has been consistently displaying high approval rates since its implementation, which clearly highlights the quality of the coverage we provide to the Taiwanese…
"Being able to adapt our operations according to latest industry trends has been one of the main factors behind our success in the country during the…
"This vaccine can really be a benefit to cancer patients and our vaccine is well-tolerated with no major safety concerns."
"Fostering the development of the pharmaceutical and biotech industries holds a central importance within President Tsai’s strategic vision to build Taiwan’s new economic model."
"The healthcare system in Mexico is large and complex and each day brings its own set of challenges"
"Our industry’s next stage will be to expand more into the international arena and gain the critical size needed to truly fulfill our global ambitions."
